KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBT: 2010-2025

Historic EBT for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to $50,000.

  • TherapeuticsMD's EBT rose 108.82% to $50,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $10,000, marking a year-over-year increase of 100.25%. This contributed to the annual value of -$2.3 million for FY2024, which is 69.74% up from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's EBT is $50,000, which was down 90.83% from $545,000 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's EBT registered a high of $50.1 million during Q4 2021, and its lowest value of -$47.4 million during Q3 2021.
  • Over the past 3 years, TherapeuticsMD's median EBT value was -$809,000 (recorded in 2024), while the average stood at -$923,455.
  • As far as peak fluctuations go, TherapeuticsMD's EBT soared by 219.16% in 2021, and later plummeted by 103.27% in 2023.
  • Over the past 5 years, TherapeuticsMD's EBT (Quarterly) stood at $50.1 million in 2021, then decreased by 3.38% to $48.5 million in 2022, then slumped by 103.27% to -$1.6 million in 2023, then soared by 105.24% to $83,000 in 2024, then spiked by 108.82% to $50,000 in 2025.
  • Its EBT was $50,000 in Q3 2025, compared to $545,000 in Q2 2025 and -$668,000 in Q1 2025.